Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment

By sjmartinez • March 19, 2023

Llovet JM, Willoughby CE, Singal AG, Greten TF, Heikenwälder M, El-Serag HB, Finn RS, Friedman SL. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat Rev Gastroenterol Hepatol. 2023 Mar 17. doi: 10.1038/s41575-023-00754-7. Epub ahead of print. PMID: 36932227.

Tags: Hematology/Oncology, Publications

Year 2. December 4. Fellowship Match Results Confirms that UCLA DoM is Among the Best in the Country.

Within the Department of Medicine (DoM) at UCLA, trainees are the heartbeat of our community. The medical students, residents, fellows, and postdocs who make up ...

Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

Cho BC, Lee JS, Wu YL, Cicin I, Dols MC, Ahn MJ, Cuppens K, Veillon R, Nadal E, Dias JM, Martin C, Reck M, Garon ...

Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)

Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth ...